MediciNova, Inc.

As of June 30, 2026, MediciNova, Inc. carries a market capitalization of 10.29B, placing it among publicly traded companies globally. Its enterprise value stands at 6.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MediciNova, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, MediciNova, Inc. has 49.22M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 68.65, and the price-to-book ratio stands at 1.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 41.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.17B versus a market cap of 10.29B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MediciNova, Inc. maintains a current ratio of 8.75, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, MediciNova, Inc. posted a negative return on equity (ROE) of -25.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.83, reflecting losses generated across the asset base. The company generates approximately 19.31M in revenue per employee across its workforce of 7.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, MediciNova, Inc.'s stock has gained approximately 21.43% over the past 52 weeks. The 50-day moving average sits at 259.30, while the 200-day moving average is 236.77.

Over the twelve months ended June 30, 2026, MediciNova, Inc. generated 149.64M in revenue and converted that into -1.75B in net income, yielding earnings per share of -35.56. EBITDA reached -1.92B, while operating income came in at -1.93B.

As of June 30, 2026, MediciNova, Inc. holds 4.13B in cash and equivalents against 19.03M in total debt, resulting in a net debt position of -4.13B. Total book value stands at 6.06B, with working capital of 3.73B providing operational flexibility.

MediciNova, Inc. produced -1.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.23M in capital expenditures, free cash flow totaled -1.48B - equivalent to -30.18 per share.

Over the twelve months ended June 30, 2026, MediciNova, Inc. posted a gross margin of 37.75, reflecting its pricing power and cost economics. The operating margin of -1,287.41 and net profit margin of -1,168.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

MediciNova, Inc.'s most recent stock split took place on November 1, 2006 with a 10:1 split ratio.

As of June 30, 2026, MediciNova, Inc. has an Altman Z-Score of -12.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.